Fig. 1: The elevated levels of IDO1 and TDO2 and their correlations with T cell infiltration in human TNBC and melanoma support targeting the key metabolite Kyn for tumor suppression. | Nature Communications

Fig. 1: The elevated levels of IDO1 and TDO2 and their correlations with T cell infiltration in human TNBC and melanoma support targeting the key metabolite Kyn for tumor suppression.

From: An in situ hydrogel-mediated chemo-immunometabolic cancer therapy

Fig. 1: The elevated levels of IDO1 and TDO2 and their correlations with T cell infiltration in human TNBC and melanoma support targeting the key metabolite Kyn for tumor suppression.The alternative text for this image may have been generated using AI.

a Schematics of the localized chemo-immunometabolic therapy enabled by an injectable hydrogel for elicitation of anti-tumor immunity and suppression of tumor growth. b, c Expression of IDO1 and TDO2 in TNBC (b) and skin cutaneous melanoma (SKCM) (c) or the corresponding normal tissues from the TCGA database, represented as transcripts per million (TPM). Whiskers extend to minimum and maximum values, horizontal bars show the median and boxes encompass 25th−75th percentiles, and statistical significance was determined by two-tailed t-test. *P < 0.05. d, e Spearman correlation of IDO1 expression with CD3E and CD8A expressions from the TCGA database for TNBC (d, n = 1085) and SKCM (e, n = 558).

Back to article page